Drug Safety Vacuum In Congress? Rep. Stupak To Leave After This Term
This article was originally published in The Pink Sheet Daily
Executive Summary
Michigan Democrat's departure leaves opening at top of House oversight panel where his investigations included Merck's handling of unfavorable Vytorin study results and FDA's approval of Ketek.
You may also be interested in...
People In The News – Tracking The Latest Industry Personnel Moves
Presidents & CEOs
People In The News – Tracking The Latest Industry Personnel Moves
Presidents & CEOs
Medicare RDS Tax May Prompt Employer Coverage Shifts, Focus On Rx Costs
Prescription drug coverage for millions of retirees currently provided by for-profit employer plans may change in the coming years as a result of the new tax on the Medicare retiree drug subsidy, signed into law as part of health reform March 23